Neurology®
The most widely read and highly cited peer-reviewed Neurology journal
Quick Search
Advanced Search
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correction (v56,p1124)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Greene, D. A.
Right arrow Articles by Brown, M. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Greene, D. A.
Right arrow Articles by Brown, M. B.
Neurology 1999;53:580
© 1999 American Academy of Neurology
Articles

Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy

D. A. Greene, MD, J. C. Arezzo, PhD, M. B. Brown, PhD and the Zenarestat Study Group*

From the Departments of Internal Medicine (Dr. Greene) and Biostatistics (Dr. Brown), University of Michigan, Ann Arbor, MI; and the Department of Neuroscience (Dr. Arezzo), Albert Einstein College of Medicine, Yeshiva University, Bronx, NY.

Address correspondence and reprint requests to Dr. Douglas A. Greene, 3920 Taubman Center, Box 0354, University of Michigan Medical Center, Ann Arbor, MI 48109-0354.

OBJECTIVE: To determine whether the aldose reductase inhibitor (ARI) zenarestat improves nerve conduction velocity (NCV) and nerve morphology in diabetic peripheral polyneuropathy (DPN).

METHODS: A 52-week, randomized, placebo-controlled, double-blinded, multiple-dose, clinical trial with the ARI zenarestat was conducted in patients with mild to moderate DPN. NCV was measured at baseline and study end. Contralateral sural nerve biopsies were obtained at 6 weeks and at the study’s end for nerve sorbitol measurement and computer-assisted light morphometry to determine myelinated nerve fiber density (number of fibers/mm2 cross-sectional area) in serial bilateral sural nerve biopsies.

RESULTS: Dose-dependent increments in sural nerve zenarestat level and sorbitol suppression were accompanied by significant improvement in NCV. In a secondary analysis, zenarestat doses producing >80% sorbitol suppression were associated with a significant increase in the density of small-diameter (<5 µm) sural nerve myelinated fibers.

CONCLUSIONS: Aldose reductase pathway inhibition improves NCV slowing and small myelinated nerve fiber loss in DPN in humans, but >80% suppression of nerve sorbitol content is required. Thus, even low residual levels of aldose reductase activity may be neurotoxic in diabetes, and potent ARIs such as zenarestat may be required to stop or reverse progression of DPN.




This article has been cited by other articles:


Home page
 Diabetes CareHome page
V. Bril, T. Hirose, S. Tomioka, R. Buchanan, and for the Ranirestat Study Group
Ranirestat for the Management of Diabetic Sensorimotor Polyneuropathy
Diabetes Care, July 1, 2009; 32(7): 1256 - 1260.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
T. D. Wiggin, K. A. Sullivan, R. Pop-Busui, A. Amato, A. A.F. Sima, and E. L. Feldman
Elevated Triglycerides Correlate With Progression of Diabetic Neuropathy
Diabetes, July 1, 2009; 58(7): 1634 - 1640.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
P. J. Dyck, J. E. Norell, H. Tritschler, K. Schuette, R. Samigullin, D. Ziegler, E. J. Bastyr III, W. J. Litchy, and P. C. O'Brien
Challenges in Design of Multicenter Trials: End points assessed longitudinally for change and monotonicity
Diabetes Care, October 1, 2007; 30(10): 2619 - 2625.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
V. R. Drel, N. Mashtalir, O. Ilnytska, J. Shin, F. Li, V. V. Lyzogubov, and I. G. Obrosova
The Leptin-Deficient (ob/ob) Mouse: A New Animal Model of Peripheral Neuropathy of Type 2 Diabetes and Obesity
Diabetes, December 1, 2006; 55(12): 3335 - 3343.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
N. Hotta, Y. Akanuma, R. Kawamori, K. Matsuoka, Y. Oka, M. Shichiri, T. Toyota, M. Nakashima, I. Yoshimura, N. Sakamoto, et al.
Long-Term Clinical Effects of Epalrestat, an Aldose Reductase Inhibitor, on Diabetic Peripheral Neuropathy: The 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial
Diabetes Care, July 1, 2006; 29(7): 1538 - 1544.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
A. G. Smith, J. Russell, E. L. Feldman, J. Goldstein, A. Peltier, S. Smith, J. Hamwi, D. Pollari, B. Bixby, J. Howard, et al.
Lifestyle Intervention for Pre-Diabetic Neuropathy.
Diabetes Care, June 1, 2006; 29(6): 1294 - 1299.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
S. Misawa, S. Kuwabara, K. Kanai, N. Tamura, M. Nakata, S. Sawai, K. Yagui, and T. Hattori
Aldose reductase inhibition alters nodal Na+ currents and nerve conduction in human diabetics
Neurology, May 23, 2006; 66(10): 1545 - 1549.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
B. Kakinoki, S. Sekimoto, S. Yuki, T. Ohgami, M. Sejima, K. Yamagami, and K.-i. Saito
Orally Active Neurotrophin-Enhancing Agent Protects Against Dysfunctions of the Peripheral Nerves in Hyperglycemic Animals
Diabetes, March 1, 2006; 55(3): 616 - 621.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
V Bansal, J Kalita, and U K Misra
Diabetic neuropathy
Postgrad. Med. J., February 1, 2006; 82(964): 95 - 100.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
V. Bril, R. A. Buchanan, and the Ranirestat Study Group*
Long-Term Effects of Ranirestat (AS-3201) on Peripheral Nerve Function in Patients With Diabetic Sensorimotor Polyneuropathy
Diabetes Care, January 1, 2006; 29(1): 68 - 72.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Vinik
Use of Antiepileptic Drugs in the Treatment of Chronic Painful Diabetic Neuropathy
J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4936 - 4945.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
F. Li, V. R. Drel, C. Szabo, M. J. Stevens, and I. G. Obrosova
Low-Dose Poly(ADP-Ribose) Polymerase Inhibitor-Containing Combination Therapies Reverse Early Peripheral Diabetic Neuropathy
Diabetes, May 1, 2005; 54(5): 1514 - 1522.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. D. Davis, L. Kiers, L. MacGregor, M. Quinn, J. Arezzo, M. Green, M. Rosenthal, M. Chia, M. Michael, P. Bartley, et al.
A Randomized, Double-Blinded, Placebo-Controlled Phase II Trial of Recombinant Human Leukemia Inhibitory Factor (rhuLIF, Emfilermin, AM424) to Prevent Chemotherapy-Induced Peripheral Neuropathy
Clin. Cancer Res., March 1, 2005; 11(5): 1890 - 1898.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
A. A.F. Sima, M. Calvani, M. Mehra, A. Amato, and for the Acetyl-l-Carnitine Study Group
Acetyl-L-Carnitine Improves Pain, Nerve Regeneration, and Vibratory Perception in Patients With Chronic Diabetic Neuropathy: An analysis of two randomized placebo-controlled trials
Diabetes Care, January 1, 2005; 28(1): 89 - 94.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
I. G. Obrosova, P. Pacher, C. Szabo, Z. Zsengeller, H. Hirooka, M. J. Stevens, and M. A. Yorek
Aldose Reductase Inhibition Counteracts Oxidative-Nitrosative Stress and Poly(ADP-Ribose) Polymerase Activation in Tissue Sites for Diabetes Complications
Diabetes, January 1, 2005; 54(1): 234 - 242.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
K. Uehara, S.-I. Yamagishi, S. Otsuki, S. Chin, and S. Yagihashi
Effects of Polyol Pathway Hyperactivity on Protein Kinase C Activity, Nociceptive Peptide Expression, and Neuronal Structure in Dorsal Root Ganglia in Diabetic Mice
Diabetes, December 1, 2004; 53(12): 3239 - 3247.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
V. Bril, R. A. Buchanan, and the AS-3201 Study Group
Aldose Reductase Inhibition by AS-3201 in Sural Nerve From Patients With Diabetic Sensorimotor Polyneuropathy
Diabetes Care, October 1, 2004; 27(10): 2369 - 2375.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
D. Ziegler
Polyneuropathy in the diabetic patient--update on pathogenesis and management
Nephrol. Dial. Transplant., September 1, 2004; 19(9): 2170 - 2175.
[Full Text] [PDF]

Home page
 Endocr. Rev.Home page
A. M. Vincent, J. W. Russell, P. Low, and E. L. Feldman
Oxidative Stress in the Pathogenesis of Diabetic Neuropathy
Endocr. Rev., August 1, 2004; 25(4): 612 - 628.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
A. J.M. Boulton, R. A. Malik, J. C. Arezzo, and J. M. Sosenko
Diabetic Somatic Neuropathies
Diabetes Care, June 1, 2004; 27(6): 1458 - 1486.
[Full Text] [PDF]

Home page
 DiabetesHome page
D. Sigaudo-Roussel, C. Demiot, B. Fromy, A. Koitka, G. Leftheriotis, P. Abraham, and J. L. Saumet
Early Endothelial Dysfunction Severely Impairs Skin Blood Flow Response to Local Pressure Application in Streptozotocin-Induced Diabetic Mice
Diabetes, June 1, 2004; 53(6): 1564 - 1569.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
M. J. Brown, S. J. Bird, S. Watling, H. Kaleta, L. Hayes, S. Eckert, and H. L. Foyt
Natural Progression of Diabetic Peripheral Neuropathy in the Zenarestat Study Population
Diabetes Care, May 1, 2004; 27(5): 1153 - 1159.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
V. Bril, Y. Ono, and R. A. Buchanan
Sural Nerve Sorbitol in Patients With Diabetic Sensorimotor Polyneuropathy
Diabetes Care, May 1, 2004; 27(5): 1160 - 1163.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
P. Kallinikos, M. Berhanu, C. O'Donnell, A. J. M. Boulton, N. Efron, and R. A. Malik
Corneal Nerve Tortuosity in Diabetic Patients with Neuropathy
Invest. Ophthalmol. Vis. Sci., February 1, 2004; 45(2): 418 - 422.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
B. F. Johnson, R. W. Nesto, M. A. Pfeifer, W. R. Slater, A. I. Vinik, D. A. Chyun, G. Law, F. J.Th. Wackers, and L. H. Young
Cardiac Abnormalities in Diabetic Patients With Neuropathy: Effects of aldose reductase inhibitor administration
Diabetes Care, February 1, 2004; 27(2): 448 - 454.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
S. M Setter, R K. Campbell, and C. J Cahoon
Biochemical Pathways for Microvascular Complications of Diabetes Mellitus
Ann. Pharmacother., December 1, 2003; 37(12): 1858 - 1866.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
S. Thrainsdottir, R. A. Malik, L. B. Dahlin, P. Wiksell, K. F. Eriksson, I. Rosen, J. Petersson, D. A. Greene, and G. Sundkvist
Endoneurial Capillary Abnormalities Presage Deterioration of Glucose Tolerance and Accompany Peripheral Neuropathy in Man
Diabetes, October 1, 2003; 52(10): 2615 - 2622.
[Abstract] [Full Text] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
R. Malik
Failure to define the pathogenesis and treatment of human diabetic neuropathy
The British Journal of Diabetes & Vascular Disease, March 1, 2003; 3(2): 107 - 111.
[Abstract] [PDF]

Home page
 DiabetesHome page
V. Asnaghi, C. Gerhardinger, T. Hoehn, A. Adeboje, and M. Lorenzi
A Role for the Polyol Pathway in the Early Neuroretinal Apoptosis and Glial Changes Induced by Diabetes in the Rat
Diabetes, February 1, 2003; 52(2): 506 - 511.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
Z. T. Bloomgarden
Neuropathy, Womens' Health, and Socioeconomic Aspects of Diabetes
Diabetes Care, June 1, 2002; 25(6): 1085 - 1094.
[Full Text] [PDF]

Home page
 BrainHome page
S. Yagihashi, S.-I. Yamagishi, R.-i. Wada, M. Baba, T. C. Hohman, C. Yabe-Nishimura, and Y. Kokai
Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitor
Brain, December 1, 2001; 124(12): 2448 - 2458.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
N. Hotta, T. Toyota, K. Matsuoka, Y. Shigeta, R. Kikkawa, T. Kaneko, A. Takahashi, K. Sugimura, Y. Koike, J. Ishii, et al.
Clinical Efficacy of Fidarestat, a Novel Aldose Reductase Inhibitor, for Diabetic Peripheral Neuropathy: A 52-week multicenter placebo-controlled double-blind parallel group study
Diabetes Care, October 1, 2001; 24(10): 1776 - 1782.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
Q. Yang, R. Kaji, T. Takagi, N. Kohara, N. Murase, Y. Yamada, Y. Seino, and H. Bostock
Abnormal axonal inward rectifier in streptozocin-induced experimental diabetic neuropathy
Brain, June 1, 2001; 124(6): 1149 - 1155.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
M. Nakayama, J. Nakamura, Y. Hamada, S. Chaya, R. Mizubayashi, Y. Yasuda, H. Kamiya, N. Koh, and N. Hotta
Aldose Reductase Inhibition Ameliorates Pupillary Light Reflex and F-Wave Latency in Patients With Mild Diabetic Neuropathy
Diabetes Care, June 1, 2001; 24(6): 1093 - 1098.
[Abstract] [Full Text]